These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 224450)
1. Substrate specificity of the human lymphokine leucocyte migration-inhibitory factor (LIF): radioenzymic assay and inhibition by cGMP. Bendtzen K Scand J Immunol; 1979; 10(1):61-7. PubMed ID: 224450 [TBL] [Abstract][Full Text] [Related]
2. Use of benzoyl-L-phenylalanyl-L-valyl-L-arginine (3H) methyl ester as a sensitive and selective substrate for the human lymphokine, leukocyte migration inhibitory factor (LIF). Bendtzen K; Rocklin RE J Immunol; 1980 Oct; 125(4):1775-81. PubMed ID: 6251137 [TBL] [Abstract][Full Text] [Related]
3. Determination of the human lymphokine leukocyte migration inhibitory factor (LIF) by a sensitive radioenzymatic assay. Inhibitory effect of cGMP on the esterolytic activity of highly purified LIF. Bendtzen K J Clin Lab Immunol; 1979 Apr; 2(1):37-43. PubMed ID: 95804 [TBL] [Abstract][Full Text] [Related]
4. Human leukocyte migration inhibitory factor (LIF). IV. 3',5'-cGMP protects LIF against inactivation by the esterase inhibitor phenylmethylsulfonyl fluoride. Bendtzen K Scand J Immunol; 1977; 6(12):1357-61. PubMed ID: 203999 [TBL] [Abstract][Full Text] [Related]
5. Human leukocyte migration inhibitory factor (LIF) III. Further investigations on the serine protease nature of this lymphokine and its preference for arginine amides. Bendtzen K Scand J Immunol; 1977; 6(10):1055-62. PubMed ID: 335493 [TBL] [Abstract][Full Text] [Related]
6. Human leukocyte migration inhibitory factor (LIF). II. Partial biochemical characterization of the substrate specificities for this lymphokine. Bendtzen K Scand J Immunol; 1977; 6(1-2):133-40. PubMed ID: 322260 [TBL] [Abstract][Full Text] [Related]
7. Human leucocyte migration inhibitory factor (LIF). V. Specific regulation of the lymphokine serine protease activity by 3',5'-cGMP and, possibly, 2',3'-cCMP. Bendtzen K Scand J Immunol; 1978; 8(1):53-61. PubMed ID: 212822 [TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization of the human lymphokine leukocyte migration inhibitory factor (LIF): role of cGMP as a specific inhibitor of the LIF esterase activity. Bendtzen K Adv Exp Med Biol; 1979; 114():485-90. PubMed ID: 223417 [No Abstract] [Full Text] [Related]
9. Increased polymorphonuclear leukocyte cGMP levels induced by the human lympholine, leukocyte migration inhibitory factor (LIF). Bendtzen K; Klysner R Immunopharmacology; 1979 Jul; 1(4):323-30. PubMed ID: 233586 [TBL] [Abstract][Full Text] [Related]
10. Some physicochemical properties of human leucocyte migration inhibitory factor (LIF). Bendtzen K Acta Pathol Microbiol Scand C; 1976 Dec; 84C(6):471-6. PubMed ID: 11637 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of human thrombin assessed with different substrates and inhibitors. Characterization of fibrinopeptide binding interaction. Gorman JJ Biochim Biophys Acta; 1975 Dec; 412(2):273-82. PubMed ID: 1191680 [TBL] [Abstract][Full Text] [Related]
12. Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors. Bendtzen K Scand J Immunol; 1977; 6(1-2):126-31. PubMed ID: 322258 [TBL] [Abstract][Full Text] [Related]
13. Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors. Bendtzen K Scand J Immunol; 1977; 6(1-2):125-31. PubMed ID: 322257 [TBL] [Abstract][Full Text] [Related]
14. Leukocyte migration inhibitory factor: a serine esterase released by stimulated human lymphocytes. Kinetic analysis and inhibition by cyclic GMP. Bendtzen K Biochim Biophys Acta; 1979 Jan; 566(1):183-91. PubMed ID: 215234 [TBL] [Abstract][Full Text] [Related]
15. The use of human lymphoid cell line lymphokine preparations (LCL-LK) as working standards in the bioassay of human leucocyte migration inhibition factor (LIF). Hamblin AS; Zawisza B; Shipton U; Dumonde DC; Den Hollander FC; Verheul H J Immunol Methods; 1982 Nov; 54(3):317-29. PubMed ID: 6757327 [TBL] [Abstract][Full Text] [Related]
16. In vitro modulation of human leucocyte migration and migration inhibitory factor (LIF) activity by cyclic 3',5'-AMP and cyclic 3',5'-GMP. Bendtzen K; Palit J Acta Pathol Microbiol Scand C; 1977 Feb; 85(1):78-80. PubMed ID: 190856 [TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a coagulant enzyme, okinaxobin I, from the venom of Trimeresurus okinavensis (Himehabu snake) which releases fibrinopeptide B. Iwasaki A; Shieh TC; Shimohigashi Y; Waki M; Kihara H; Ohno M J Biochem; 1990 Nov; 108(5):822-8. PubMed ID: 1964457 [TBL] [Abstract][Full Text] [Related]
18. Kinetic peculiarities of human tissue kallikrein: 1--substrate activation in the catalyzed hydrolysis of H-D-valyl-L-leucyl-L-arginine 4-nitroanilide and H-D-valyl-L-leucyl-L-lysine 4-nitroanilide; 2--substrate inhibition in the catalyzed hydrolysis of N alpha-p-tosyl-L-arginine methyl ester. Sousa MO; Miranda TL; Maia CN; Bittar ER; Santoro MM; Figueiredo AF Arch Biochem Biophys; 2002 Apr; 400(1):7-14. PubMed ID: 11913965 [TBL] [Abstract][Full Text] [Related]
19. Production of leucocyte inhibitory factor (LIF) and macrophage inhibitory factor (MIF) by PHA-stimulated lymphocytes. Ruthlomnitzer ; Rabson AR; Koornhof HJ Clin Exp Immunol; 1975 Dec; 22(3):522-7. PubMed ID: 773578 [TBL] [Abstract][Full Text] [Related]
20. Human leucocyte response to migration inhibitory activity from lymphocytes. Modification by aprotinin, Tranexamic acid and phenylmethyl sulfonylfluoride. Coeugniet E; Søeberg B; Bendixen G Acta Med Scand; 1978; 203(3):191-5. PubMed ID: 305717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]